$427.39
Value $12.5B
MDGL and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$427.39
Value $12.5B
$700.22
Value $260B
Madrigal Pharmaceuticals (MDGL) has a market value of $12.5B and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, MDGL moved -19.2% and TMO +19.5%. Dividend yield: MDGL none, TMO 0.26%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MDGL$12.5B
TMO$260B
TMO is 21 times MDGL
Revenue, 12 months
MDGL$1.4B
TMO$47.4B
TMO is 33 times MDGL
Net income, 12 months
MDGL-$155M
TMO$7.1B
Operating margin
MDGL-10.7%
TMO17.9%
28.6 points apart
ROIC
MDGL-13.0%
TMO8.2%
21.2 points apart
P/E
MDGL–
TMO36.8
Dividend yield
MDGL0.0%
TMO0.3%
0.3 points apart
5-year return
MDGL+370.5%
TMO+11.8%
358.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MDGL+370.5%
TMO+11.8%
| Period | MDGLWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -19.2%Price -19.2% | +19.5%Price +19.1% |
| 3 years since November 13, 2023 | +192.7%+43.1% a yearPrice +192.7% | +58.8%+16.7% a yearPrice +57.3% |
| 5 years since November 12, 2021 | +370.5%+36.3% a yearPrice +370.5% | +11.8%+2.3% a yearPrice +10.2% |
| 10 years since November 15, 2016 | +2,414.1%+38.1% a yearPrice +2,414.1% | +384.5%+17.1% a yearPrice +371.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MDGLMadrigal PharmaceuticalsTMOThermo Fisher Scientific
| Price | $427.39 | $700.22 |
|---|---|---|
| Market value | $12.5B | $260B |
| Enterprise value (EV) | $11.9B | $295B |
| P/E | – | 36.8 |
| P/E, 5-year median | – | 32.7 |
| P/B | 19.9 | 4.8 |
| EV/EBIT | – | 34.9 |
| Free cash flow yield | – | 2.9% |
| Revenue, 12 months | $1.4B | $47.4B |
|---|---|---|
| Net income, 12 months | -$155M | $7.1B |
| Free cash flow, 12 months | -$169M | $7.6B |
| Earnings per share, 12 months | -$8.14 | $18.96 |
| Revenue growth, year on year | 432.1% | 3.9% |
| Revenue growth a year, past | – | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | – | – |
|---|---|---|
| Operating margin | -10.7% | 17.9% |
| Net margin | -10.9% | 14.9% |
| ROIC | -13.0% | 8.2% |
| ROE | -26.6% | 13.4% |
| Cash | $961M | $6.1B |
|---|---|---|
| Total debt | $386M | $41.4B |
| Net debt / EBITDA | – | 3.7 |
| Interest cover | -4.8× | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($260B) is about 20.8 times Madrigal Pharmaceuticals ($12.5B), at today's prices.
Since November 15, 2016, MDGL's price moved +2,414.1% and TMO's +371.0%. With dividends: MDGL +2,414.1% (+38.1% a year), TMO +384.5% (+17.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Madrigal Pharmaceuticals and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
Over the last twelve months, the net margin was -10.9% for Madrigal Pharmaceuticals and 14.9% for Thermo Fisher Scientific, and the operating margin -10.7% and 17.9%. Revenue was $1.4B and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.